Stockreport

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitr [Read more]